drugset / Trial / NCT04425031

Handling Oxygenation Targets in COVID-19

NCT04425031 ↗

RandomizedParallel-groupSingle-blindPrevention

Summary

Patients with COVID-19 and hypoxaemic respiratory failure and admitted to the intensive care unit (ICU) are treated with supplementary oxygen as a standard. However, quality of quantity evidence regarding this practise is low. The aim of the HOT-COVID trial is to evaluate the benefits and harms of two targets of partial pressure of oxygen in arterial blood (PaO2) in guiding the oxygen therapy in acutely ill adult COVID-19 patients with hypoxaemic respiratory failure at ICU admission.

Timeline

Start
2020-08-25
Primary completion
2023-03-08
Completion
2024-03-08

Outcome

Met primary endpoint

paper supplemental bootstrapped adjusted mean difference, 5.8 days [95% CI, 0.2-11.5 days]; P = .04 PMID 38501214 ↗

paper resulted in more days alive without life support in 90 days than targeting a Pao2 of 90 mm Hg. PMID 38501214 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxygen Other / unclassified — —